Alvaro Alencar, MD
Hematology & Oncology · Miami, FLNPI 1417159633
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $111,749 of the $140,382 with a category attached, or 79.6%. 26 manufacturers reported payments, led by Lilly USA, LLC at 44.4% of the total. 2025 is the largest year on record at $65,833, 5.8 times the $11,328 reported in 2019. Among hematology & oncology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 121 payments — averaging $1160.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$62K
- ADC Therapeutics America, Inc.$13K
- Amgen$11K
- Dr.reddy's Laboratories,inc.$6K
- TG Therapeutics, Inc.$5K
- Beone Medicines USA, Inc.$5K
- plus $38K from 20 others
Across 30 payments — averaging $59,677 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.4M
- Incyte Corporation$212K
- Beigene USA, Inc.$137K
- E.r. Squibb & Sons, L.L.C.$50K
What the payments were for
- Consulting fees$111,74980%
- Speaking & faculty fees$20,47315%
- Travel & lodging$4,2563%
- Food & beverage$3,6103%
- Education$2950%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 17 | $62,378 |
| ADC Therapeutics America, Inc. | 11 | $12,606 |
| Amgen | 4 | $11,143 |
| Dr.reddy's Laboratories,inc. | 4 | $6,350 |
| TG Therapeutics, Inc. | 4 | $5,400 |
| Beone Medicines USA, Inc. | 5 | $4,852 |
| Incyte Corporation | 8 | $4,758 |
| Gilead | 8 | $4,744 |
| Beigene USA, Inc. | 7 | $4,263 |
| Spectrum Pharmaceuticals Inc. | 12 | $3,403 |
| Genmab U.S., Inc. | 8 | $3,206 |
| AstraZeneca | 4 | $3,170 |
| Deciphera Pharmaceuticals Inc. | 1 | $2,480 |
| AbbVie | 6 | $2,427 |
| Genentech USA, Inc. | 5 | $2,363 |
| Johnson & Johnson | 2 | $1,536 |
| Seagen Inc. | 4 | $1,525 |
| Bristol Myers Squibb | 2 | $1,358 |
| Epizyme, Inc. | 1 | $1,250 |
| Beigene, Ltd. | 1 | $688 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $195 |
| Rigel Pharmaceuticals, Inc. | 1 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $100 |
| Tempus AI, Inc | 1 | $29 |
| Dova Pharmaceuticals | 1 | $19 |
| Pfizer | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$140,382 in reported general payments places this provider in the 90th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 80 | $1,114,799 |
| ImbruvicaIbrutinib | 27 | $661,056 |
| JaypircaPirtobrutinib | 23 | $510,486 |
| CalquenceAcalabrutinib Maleate | 26 | $400,250 |
| VenclextaVenetoclax | 19 | $291,599 |
| Atovaquone | 12 | $2,033 |
| Acyclovir | 138 | $1,171 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 115 | $509 |
| Dexamethasone | 24 | $303 |
| Ondansetron Hcl | 28 | $189 |
| Prochlorperazine Maleate | 14 | $122 |
| Allopurinol | 29 | $87 |
| Prednisone | 32 | $81 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $4,263 | $1,114,79980 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $195 | $661,05627 claims |
| Lilly USA, LLCJaypirca | $62,378 | $510,48623 claims |
| AstraZenecaCalquence | $3,170 | $400,25026 claims |
| AbbVieVenclexta | $2,427 | $291,59919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Miami
- Steven FeinMiami$1M
- Srikanth NagallaMiami$639K
- Neil NagovskiMiami$530K
- Carl LandgrenMiami$517K
- Raja MudadMiami$422K
- George NahasMiami$364K
- Fernando de ZarragaMiami$333K
- Mikkael SekeresMiami$278K
- Krishna KomanduriMiami$187K
- Estelamari RodriguezMiami$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.